Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

1475-2840-7-20 1475-2840 Original investigation Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment Farah Raymond raymond.f@ziv.health.gov.il Shurtz-Swirski Revital revssh@gmail.com Lapin Olga olgal@hotmail.com

Departement of Internal Medicine B, Ziv Medical Center, Safed, Israel

Eliachar Research Laboratory, Western Galilee Hospital, Nahariya, Israel

Cardiovascular Diabetology 1475-2840 2008 7 1 20 http://www.cardiab.com/content/7/1/20 1857067810.1186/1475-2840-7-20 06 3 2008 22 6 2008 22 6 2008 2008 Farah et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

The metabolic deregulation associated with diabetes mellitus (DM) causes secondary pathophysiologic changes in multiple organ systems. Endothelial injury is induced by oxidative stress (OS) and inflammation. We have previously shown that DM type 2 patients are exposed to increased OS and inflammation contributed in part by primed peripheral polymorphonuclear leukocytes (PMNLs).

Aims

To characterize the effect of oral medication on PMNL priming, on PMNL-related and on systemic inflammation, in correlation to changed diabetes parameters in patient with newly diagnosed type 2 DM.

Methods

PMNLs were separated from DM patient's prior and following treatment with either metformin (Glucophage), or Thiazolidinedione (rosiglitazone) and from healthy control subjects (HC). Rate of superoxide release from phorbol ester-stimulated PMNLs and CD11b on PMNLs assessed PMNL priming. White blood cells (WBC) and PMNL counts and apoptosis reflected PMNL-related inflammation. CRP, fibrinogen, transferrin and albumin blood levels reflected systemic inflammation.

Results

Both metformin and rosiglitazone treatments reduced significantly the high levels of glucose and HbA1c, and slightly improved lipid profile during 2 months. PMNL priming parameters, higher compared to HC, increased after 2 months of metformin treatment. Rosiglitazone treatment decreased PMNL priming. ALP, higher in DM, significantly decreased following 2 months of both treatments. Systemic inflammation markers (fibrinogen, CRP), higher in DM, decreased following both treatments. Transferrin and albumin were similar to HC. PMNL-related inflammation markers were higher in DM; however, only PMNL apoptosis decreased after both treatments. Monocyte counts, higher in DM compared to HC, decreased following both treatments. Serum insulin levels, higher in DM compared to HC, decreased following both treatments. PMNL-related priming and inflammation parameters positively correlated with HbA1c.

Conclusion

The present research adds new facet in evaluating anti-hyperglycemic treatment in type 2 DM patients. Despite sufficient glycemic control using both treatments, some PMNL-related parameters deteriorated. Thus, anti hyperglycemic treatment should be favored due to its combined anti-PMNL priming and anti-inflammatory effect, in addition to its anti-hyperglycemic characteristics, according to the correlation among these parameters. Such combined treatment may reduce morbidity and mortality common in DM patients.

Background

Atherosclerosis begins during adolescence in otherwise healthy individuals; it develops earlier in type 2 diabetic patients and frequently is the leading cause of premature mortality. Whereas there is now highly persuasive evidence that glycemic control reduces the the risk of microvascular complications in type 1 diabetes, and probabily in type 2 diabetes as well, such evidence is unavailable for macrovascular complications. There is a close linkage bettween rapidly developing atherosclerosis in diabetic patients and endothelial dysfunction and insulin resistance in diabetes mellitus 123. Endothelial dysfunction appears to predate the development of diabetic angiopathy and play a key role in the pathogenesis of diabetic angiopathy in man. Insulin resistance, oxidative stress, and inflammation all play a key role and participate in the development of endothelial dysfunction 4567. Much evidence support the presence of insulin resistance as the fundamental pathophysiologic disturbance for the clauster of metabolic and cardiovascular disorders, known as the metabolic syndrome. Oxidative stress is believed to play a role in diabetic-induced vascular complication 8910. Chronic exposure to increased levels of hydroxyl radicals in vivo likely plays a significant role in the origine of diabetes-associated endothelial dysfunction. Diabetic endothelium produce increase in both superoxide anion radicals and hydrogen peroxide leading to enhanced intracellular production of hydroxyl radicals that could be implicated in diabetes-induced endothelial dysfunction. Chronic treatment with a known hydroxyl radical scavenger, dimethylthiourea, could prevent endothelial dysfunction in diabetes. Other indicators for the oxidative stress in diabetes the elevated levels of advanced glycation end products (AGE) that rise in parallel with the severity and complications of the disease 1112, as we can demonstrate this during the elevation of HbA1c in diabetes 13. We have previously shown that in other clinical situations known to be associated with endothelial dysfunction and accelerated atherosclerosis such as uremia, hypertension and type 2 diabetes, PMN are primed, contributing to OS and inflammation 141516. PMNLs from diabetic patients demonstrated defects in LPS-induced apoptosis. High-glucose environment may mediate these findings. The inability of diabetic neutrophils to reduce apoptosis following LPS exposure resulted in relatively increased apoptosis. This would cause decreased functional longevity of neutrophils and increased neutrophil clearance from infectious sites, possibly contributing to the increased susceptibility and severity of infections in diabetic patients 17. Other inflammatory markers found in diabetes as elevated levels of sCD14 18, fibrinogen and CRP that shown a significant correlation with PMNLs 1920. Monocytes are the principal inflammatory cells associated with the plaque formation, adherence of monocytes to the arterial wall is an early event in the development of atherosclerotic lesions. In uncontrolled diabetes with elevated HbA1c as in hyperglycemia in vitro, the peripheral blood monocytes are preferentially recruited to the intima early in the development of atheroma, they adhere to endothelium, migrate to the subendothelial space, and trasformed into lipid-lader foamy macrophages 2122232425. High doses of vitamin E (800 IU/day) can decrease the recruitment of monocytes to endothelim and cause decrement in oxidized LDL and the level of various plasma interleukines 2224. Therefore any drug that can decrease the activation of PMNLs or the monocytes, oxidative stress and inflammation should be preferable and better than drugs that treat only the hyperglycemia. Thus, in the present study we compare PMNL priming parameters in diabetic patients, treated daily with metformin for two months to those treated with rosiglitazone.

Research design and methods

Study population

Thirty untreated DM patients patients were included in this study: All the participants in this study were in age range of 30–65 year and nonsmokers. Patients underwent medical evaluation including opthalmoscopic examination, ECG and laboratory tests. The following exclusion criteria that were applied for the diabetic patients: significant dyslipidemia – LDL-cholesterol ≥ 130 mg%, HDL-cholesterol ≤ 35 mg%, triglycerides ≥ 400 mg%; evidence for microvascular diseases (diabetic retinopathy and diabetic nephropathy) and evidence for macrovascular disease (coronary artery disease, cerebrovascular disease and peripheral vascular disease); obese, BMI ≥ 30; Blood pressure > 130/85.

The untreated DM patients were further enrolled in a prospective longitudinal study, being followed up for 4 and 8 weeks of either metformin (850 mg/day) or rosiglitazone (4 mg/day) treatment.

A group of age- and gender-matched healthy controls (HC, n = 20) were included in the study. The inclusion of HC participants was based upon a clinical examination with laboratory confirmation. Patients and subjects gave informed consent for blood sampling approved by the institutional committee in accordance with the Helsinki declaration.

PMNL and sera separation

Blood was drawn in the morning after an overnight fast from hyperlipidemic patients and HC for the determination of biochemical and hematological parameters and for PMNL isolation. PMNL isolation was carried out from a 20 mL heparinized blood sample as previously described 151626. The separated PMNLs (>98% pure, approximately 10⁷cells per isolation) were resuspended in phosphate buffered saline (PBS) containing 0.1% glucose. Sera were used for the determination of C-reactive protein (CRP), albumin and transferrin while plasma served for fibrinogen quantification.

PMNL priming

a. Rate of superoxide release

The measurements of the rate of superoxide release are based on superoxide dismutase (SOD) inhibitable reduction of 80 μM cytochrome C (Sigma, St. Louis, MO., USA) to its ferrous form. The rate of superoxide release was monitored from 10⁶separated PMNLs at 22°C up to 90 min as previously described 151627.

b. Membrane CD11b

The PMNL membrane adhesion molecule CD11b was determined by flow cytometry, reflecting PMNL priming 28. Whole blood was treated with 0.1% formic acid to lyse the erythrocytes, and mouse anti human-CD11b phycoreythrin (PE)-conjugated antibody (Immunotech, Marseille, France) was added. Anti-human CD16 PC5-conjugated antibody (Immunotech, Marseille, France) was also used in all samples to enable gating on the PMNL population.

PMNL-derived inflammation

a. WBC, PMNL and monocyte counts

Counts of WBC, PMNLs and monocytes from blood drawn in EDTA were performed by an automated cell counter (Coulter STKS, Miami, Fla., USA).

b. Analysis of apoptotic PMNLs

Apoptosis was determined in whole blood from 20 randomly chosen hyperlipidemic patients and 20 HC by flow cytometry according to Kuypers et al. 29. Briefly, Annexin V kit (Bender MedSystems, Vienna, Austria) was applied to blood samples after lysis of red blood cells by Q prep (Beckman Coulter, Fullerton, California, USA). Monoclonal anti-CD16 labeled with PC5, was used for gating on PMNLs.

Systemic inflammation

a. Positive acute phase protein

Fibrinogen and CRP

Fibrinogen levels were measured in plasma using the K-Assay^®kit (Kamiya Biomedical Company) by chemical analyzer (Cobas Mira, Roche Diagnostics, Germany). Blood CRP levels were measured using commercial kit (Biokit, Spain) by the Hitachi 917 Automatic analyzer (Roche Diagnostics, Germany).

b. Negative acute phase proteins

Albumin and transferrin

Blood albumin (Alb plus, Roche Diagnostics, Manheim, Germany) and transferrin (Transferrin ver.2, Roche Diagnostics, Manheim, Germany) levels were measured using the Hitachi 917 Automatic analyzer (Roche Diagnostics, Germany).

Statistical Analysis

Data values are means ± SD. The two groups were compared by student t-test, using Prism version 3.0 statistical software (GraphPad software, San Diego, Ca). Correlations between different study parameters were performed using Pearson correlation coefficients. P < 0.05 was considered significant.

Results

Study population

Table 1 summarizes the biochemical characteristics of the participants. All studied groups of patients showed similar age range, blood pressure values, serum cholesterol, serum triglycerides, and liver enzymes, without showing target organ damage. Most traditional risk factors were similar during antihyperglycemic treatment period. ALP was higher in DM compared to HC and decreased during 2 months of both treatments (Table 1). Along with its role as an hepatic enzyme, former studies have shown significantly higher blood level of this enzyme in hypertensive patients and rats, following degranulation from primed PMNLs 14. The present study adds DM patients to this finding, and shows ameliorating results following both antihyperglycemic treatment.

Table 1

The changes in DM patients' parameters.

Parameters

Metformin

(months)

Rosiglitazone

(months)

Fundus

neg

MAP (mm Hg)

87.0 ± 2.2

99 ± 3.2

98.1 ± 1.4

99.1 ± 3.6

96.1 ± 2.0

96.2 ± 0.2

Glucose (mg/dL)

94.0 ± 11.9

228.4 ± 15.1^b

135.3 ± 8.3^a,b

135.9 ± 3.2^a,b

235.2 ± 15.8^b

143.1 ± 14.1^a,b

HbA1c (μmol/L)

5.4 ± 0.2

8.9 ± 0.3^b

7.2 ± 0.5^a,b

7 ± 0.1^a,b

10.7 ± 0.6^b

7 ± 0.3^a,b

Calculated GFR

94.6 ± 2.9

99.5 ± 2.1

95.7 ± 2.0

94.6 ± 2.9

95.4 ± 4.8

90.1 ± 4.1

Cholesterol (mg/dL)

205.0 ± 1.7

203 ± 8.6

188.3 ± 9.9

188.3 ± 2.2

207.3 ± 9.0

195.1 ± 4.8

Triglycerides (mg/dL)

120.4 ± 3.2

153.2 ± 2.1

114.6 ± 26.3

129.3 ± 6.5

190.2 ± 3.5

141.4 ± 5.5

HDL (mg/dL)

58.6 ± 0.7

45.9 ± 2.5

44.7 ± 3.4

43.9 ± 0.9

42.04 ± 2.4

41.3 ± 0.9

LDL (mg/dL)

114.6 ± 1.3

128.4 ± 7.5

120.7 ± 8.7

118.6 ± 2.1

130.0 ± 7.7

114.7 ± 2.6

Hb (g/dL)

14.3 ± 0.1

14.6 ± 0.4

14.0 ± 0.6

14.8 ± 0.5

14.7 ± 0.3

14.4 ± 0.1

ALT (U/L)

20.3 ± 0.5

27.3 ± 2.8

28.4 ± 5

20.3 ± 0.5

33.5 ± 6.5

24.3 ± 0.7^a

AST (U/L)

19.6 ± 0.3

19.2 ± 1.5

24 ± 3.6

19.6 ± 0.3

23 ± 3

17.4 ± 0.3^a

ALP (U/L)

76.2 ± 6.1

87.3 ± 4.8^b

73.7 ± 3.9^a

76.2 ± 6.1^a

83.8 ± 4.5^b

75.3 ± 1.5^a

LDH (U/L)

283.3 ± 1.9

311 ± 17

273.2 ± 10.8

283.3 ± 1.9

270.4 ± 10.8

255.8 ± 3.3

Insulin (μU/mL)

7.6 ± 0.8

15.2 ± 1.4^b

13.5 ± 1.0^b

11.1 ± 0.9^a,b

17.5 ± 1.8^b

9.5 ± 0.4^a,b

^aP < 0.05, treated DM patients vs. untreated DM patients;

^bP < 0.05, untreated DM patients vs. HC subjects

The diabetes characteristics over 8 weeks period of antihyperglycemic treatment is depicted in Table 1: Blood HbA1c and glucose levels significantly decreased following both treatment. Insulin levels, significantly higher in DM compared to HC, decreased following both antihyperglycemic treatment (Table 1).

Effect of metformin and rosiglitazone on diabetes characteristics and PMNL priming-related parameters

PMNL priming parameters revealed different picture with each antihyperglycemic treatment; the metformin-treated patients showed significant increase in PMNL priming, as reflected by significant increase either in the rate of superoxide release from separated PMNLs or in CD11b levels on PMNLs (Fig. 1a and 1b, respectively). However, the rosiglitazone treatment inhibited significantly either the rate of superoxide release from separated PMNLs or in CD11b levels on PMNLs (Fig. 1a and 1b, respectively). It has to be emphasized that both groups of patients showed higher values of PMNL priming compared to those measured in HC subjects.

Figure 1

PMNL priming parameters, namely, rate of superoxide release (a) and PMNL CD11b levels (b), before and following 1 and 2 months of either metformin (blank) or combined Roziglytazone (dotted) treatment. Data are mean ± SEM. ^aP < 0.05, vs. HC subjects; ^bP < 0.05, vs. untreated DM patients.

PMNL-derived inflammation

a. WBC, PMNL and monocytes counts

Counts of WBC and PMNLs, significantly higher in DM compared to HC, decreased only after rosiglitazone treatment, while metformin treatment caused a rise in these cells' count (Table 2). The significant higher level of monocytes in DM patients, decreased significantly after both antihyperglycemic treatments (Table 2).

Table 2

The changes in DM patients' inflammation parameters.

Parameters

Metformin

(months)

Rosiglitazone

(months)

WBC × 10⁹

6.7 ± 0.1

7.3 ± 0.3^b

7.4 ± 0.4

7.5 ± 0.2

7.04 ± 0.5^b

6.8 ± 0.6

PMNLs × 10⁹

4.0 ± 0.1

4.6 ± 0.3^b

4.7 ± 0.2

4.9 ± 0.1

4.2 ± 0.4^b

4.4 ± 0.5

PMNL apoptosis (%)

4.0 ± 0.1

12.7 ± 3.4^b

9.5 ± 2.8^{a, b}

6.5 ± 1.0^a

20.4 ± 4.4^b

7.5 ± 1.9^a

Monocytes × 10⁹

0.36 ± 0.02

0.44 ± 0.05^b

0.40 ± 0.04^b

0.39 ± 0.04^a

0.49 ± 0.03^b

0.39 ± 0.01^a

Fibrinogen (mg/dl)

304.6 ± 17.6

440.1 ± 25.2^b

471.1 ± 28.8^b

415.9 ± 41.2^{a, b}

400 ± 16.6^b

332.8 ± 8.1^a,b

Albumin (g/dl)

4.6 ± 0.05

4.53 ± 0.1

4.74 ± 0.1

4.7 ± 0.04

4.5 ± 0.1

4.6 ± 0.1

Transferrin (g/dl)

273.2 ± 10.6

274.6 ± 8.4

276.7 ± 7.2

287.9 ± 7.7

264.7 ± 7.6

286.2 ± 8.9

CRP (mg/L)

1.5 ± 0.1

8.3 ± 1.6^b

6.6 ± 1.1^b

5.8 ± 1.5^{a, b}

4.3 ± 0.9^b

1.8 ± 0.2^a,b

^aP < 0.05, treated DM patients vs. untreated DM patients;

^bP < 0.05, untreated DM patients vs. HC subjects

b. Analysis of apoptotic PMNLs

Apoptosis of PMNLs, higher in DM, decreased significantly after both antihyperglycemic treatments (Table 2).

Systemic inflammation

a. Positive acute phase protein

Fibrinogen and CRP levels, higher in DM, decreased significantly after both antihyperglycemic treatments (Table 2).

b. Negative acute phase proteins

Albumin and transferrin levels were similar to HC and did not change following antihyperglycemic treatment (Table 2).

Severity of diabetes and OS

Blood HbA1c but not blood glucose levels were significantly positively correlated with the rates of superoxide release from PMA-stimulated PMNLs separated from all studied DM patients (R = 0.4, P = 0.004, Figure 2A; R = 0.081, P = 0.52, Figure 2B, respectively). Similar correlation was found with the second parameter of PMNL priming, namely CD11b (R = 0.4; P = 0.03). Similarly, Blood HbA1c levels were significantly positively correlated with WBC (R = 0.4, P = 0.005) or with PMNL counts (R = 0.5, P = 0.0008; Figure 3, respectively). These findings are indicative of relation between OS and the severity the disease, as reflected by HbA1c levels.

Figure 2

Correlation between the rates of superoxide release from separated PMA-stimulated PMNLs and either blood HbA1c (A) or blood glucose levels (B)

Correlation between the rates of superoxide release from separated PMA-stimulated PMNLs and either blood HbA1c (A) or blood glucose levels (B). Data refers to values from DM patients and HC subjects.

Figure 3

Correlation between blood HbA1c levels and either (A) WBC or PMNL (B) counts

Correlation between blood HbA1c levels and either (A) WBC or PMNL (B) counts. Data refers to values from DM patients and HC subjects.

Discussion

Our results show that type 2 diabetic patients are exposed to oxidative stress and chronic inflammation (partially because of the primed state of their PMNLs) before any clinical evidence of angiopathy exist 15. When separated, PMA-stimulated diabetic PMNLs release superoxide significantly faster than normal control PMNLs and concomitantly with a reduced level of the plasma antioxidant GSH, predisposing these patients to OS 15. Thirty untreated DM patients patients were included in this study: All the participants in this study were in age range of 30–65 year and nonsmokers. Patients underwent medical evaluation including opthalmoscopic examination, ECG and laboratory tests. The untreated DM patients were further enrolled in a prospective longitudinal study, being followed up for 4 and 8 weeks of either metformin (850 mg/day) or rosiglitazone (4 mg/day) treatment. A group of age- and gender-matched healthy controls (HC, n = 20) were included in the study.

Blood HbA1c and glucose levels significantly decreased following both treatment. Insulin levels, significantly higher in DM compared to HC, decreased following both antihyperglycemic treatment. Lipid profile (LDL-C, triglycerides) was also improved after two months following antihyperglycemic treatment as was described in literature 25. PMNL priming parameters revealed different picture with each antihyperglycemic treatment; the metformin-treated patients showed significant increase in PMNL priming, as reflected by significant increase either in the rate of superoxide release from separated PMNLs or in CD11b levels on PMNLs. However, the rosiglitazone treatment inhibited significantly either the rate of superoxide release from separated PMNLs or in CD11b levels on PMNLs. It has to be emphasized that both groups of patients showed higher values of PMNL priming compared to those measured in HC subjects. ALP was higher in DM compared to HC and decreased during 2 months of both treatments. Along with its role as an hepatic enzyme, former studies have shown significantly higher blood level of this enzyme in hypertensive patients and rats, following degranulation from primed PMNLs 14. The present study adds DM patients to this finding, and shows ameliorating results following both antihyperglycemic treatment. Counts of WBC and PMNLs, significantly higher in DM compared to HC, decreased only after rosiglitazone treatment, while metformin treatment caused a rise in these cells' count. The significant higher level of monocytes in DM patients, decreased significantly after both antihyperglycemic treatments. Albumin and transferrin levels were similar to HC and did not change following antihyperglycemic treatment. Other inflammatory markers like fibrinogen and CRP levels, higher in DM, decreased significantly after both antihyperglycemic treatments. Apoptosis of PMNLs, higher in DM, decreased significantly after both antihyperglycemic treatments. Blood HbA1c but not blood glucose levels were significantly positively correlated with the rates of superoxide release from PMA-stimulated PMNLs separated from all studied DM patients (R = 0.4, P = 0.004, R = 0.081, P = 0.52, respectively). Similar correlation was found with the second parameter of PMNL priming, namely CD11b (R = 0.4; P = 0.03). Similarly, Blood HbA1c levels were significantly positively correlated with WBC (R = 0.4, P = 0.005) or with PMNL counts (R = 0.5, P = 0.0008; respectively). These findings are indicative of relation between OS and the severity of the disease, as reflected by HbA1c levels. Likewise, multiple clinical trials show that reduction of HbA1c and blood glucose with the known antihyperglycemic treatments was optimal but all other inflammatory markers were worsen during the same treatment 212223242526. There is a great disagreement if tight control of glycaemia and decreasing HbA1c is sufficient to prevent the danger and risk for cardiovascular diseases and atherosclerosis.

Conclusion

Our present research adds new facet in evaluating anti-hyperglycemic treatment in type 2 DM patients. Despite sufficient glycemic control achieved using both treatments, some PMNL-related parameters deteriorated. Thus, anti hyperglycemic treatment should be favored due to its combined anti-PMNL priming and anti-inflammatory effect, in addition to its anti-hyperglycemic characteristics, according to the correlation among these parameters. Such combined treatment may reduce morbidity and mortality common in DM patients 3031. Multiple other studies showed the beneficial effects of Thiazolidinediones (rosiglitazone) on cardiovascular disease in diabetes beyond improving blood glucose control 3233343536. There is a great need to complete this research with more time periods and sample to check the relation between the OS index and other inflammatory markers and the various anti hyperglycemic treatments in the reduction of mortality and morbidity.

Abbreviations

DM: Diabetes mellitus; HbA_1c: glycosylated hemoglobin A; HC: healthy control subjects; OS: oxidative stress; PMA: phorbol 12-myristate 13-acetate; PMNLs: polymorphonuclear leukocytes; ROS: reactive oxygen species; SOD: superoxide dismutase.

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes Stern MP Arch Fam Med 1998 7 2 155 162 10.1001/archfami.7.2.155 9519921 Medical management of type 2 diabetes American Diabetes Association 4 1998 10 108 Coronary risk factor, endothelial function, and aatherosclerosis: a review Vogel RA Clin Cardiol 1997 20 426 432 9134272 Epidemiology of macrovascular disease in diabetes Laakso M Lehto S Diabetes Rev 1997 5 294 295 Endothelial dysfunction and pathogenesis of diabetic angipathy Stehouwer CD Labmert J Donker AJ van Hinsbergh VW Cardiovasc Res 1997 34 55 68 10.1016/S0008-6363(96)00272-6 9217873 Endothelial dysfunction: cause of the insulin esistence syndrome Pinkley J Stehouwer C coppack S Yudkin J Diabetes 1997 46 S9 S13 9285492 Oxidative stress and atherosclerosis Kunitomo M Yakugaku Zasshi 2007 127 1997 2014 10.1248/yakushi.127.1997 18057788 The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study Gorter PM Visseren FL Algra A Graaf van der Y on behalf of the SMART Study Group Diabet Med 2007 24 1352 1360 10.1111/j.1464-5491.2007.02323.x 18042079 Metabolic syndrome and type 2 diabetes: lipid and physiological consequences Chapman MJ Diab Vasc Dis Res 2007 4 Suppl 3 S5 8 17935058 Coronary artery responses to physiologic stimuli are impoved by desferoxamine but not by L-arginine on non-insulin-dependent diabetic patiens with angiographically normal coronary arteries and no other risk factors Nitenberg A Paycha F Ledoux S Sachs R Attali JR Valensi P Circulation 1998 97 736 743 9498536 New biomarkers of Maillard reaction damage to proteins Wells-knecht KJ Brinkmann E Welle-Knecht Mc Litcfield JE Ahmed Mu Reddy S Zyzak DV Thorpe SR Baynes JW Nephrol Dial Transplant 1996 11 suppl 5 41 47 9044306 Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications Sesni M Pricci F Andreani D Di Mario U Diabetes Res 1991 16 1 9 1818791 Long term assessment of glucose control by haemoglobin-AGE measurment Wolfenbuttel BHR Giordano D Founds HW Bucala R Lancet 1996 347 513 515 10.1016/S0140-6736(96)91141-1 8596270 Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension Kristal B Shurtz-Swirski R Shapiro G Chezar J Manaster J Shasha SM Sela S Am J Hypertens 1998 11 921 928 10.1016/S0895-7061(98)00099-5 9715783 Involvement of polymorphonuclearleukocytes in oxidative stress and inflammation in type 2 diabetes Shurtz-Swirski R Sela S Shapiro G Nasser L Shasha SM Kristal B Diabetes care 2001 24 104 110 10.2337/diacare.24.1.104 11194213 The Primed Peripheral Polymorphonuclear Leukocyte – a Culprit Underlying Chronic Low-Grade Inflammation and Systemic Oxidative Stress in Chronic Kidney Disease Sela S Shurtz-Swirski R Cohen-Mazor M Mazor R Chezar J Shapiro G Hassan K Shkolnik G Geron R Kristal B J Am Soc Nephrol 2005 16 2431 2438 10.1681/ASN.2004110929 15987755 Absence of lipopolysaccaride-induced inhibition of neutrophil apoptosis in patients with diabetes Tennenberg SD Finkenauer R Dwivedi A Arch Surg 1999 134 1229 1233 10.1001/archsurg.134.11.1229 10555638 CD14 C(-260) → T Polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease Koenig W Khuseyinova N Hoffman MM Marz W Frohlich M Hoffmeister A Brenner H Rothenbacher D J Clin Invest 1986 77 1233 1243 424465 3485659 10.1172/JCI112426 Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein Yasunari K Meada Nakamura M Yoshikawa J Hypertension 2002 39 777 780 10.1161/hy0302.104670 11897762 Increased breath biomarker of oxidative stress in diabetes mellitus Phillips M Cataneo N Renee Cheema T Greenberg J Clin Chim Acta 2004 334 1-2 189 194 10.1016/j.cccn.2004.02.025 Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus Huang A Raskin P Treat Endocrinol 2005 4 205 220 10.2165/00024677-200504040-00002 16053338 Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control Md Isa SH Najihah I Nazaimoon WM Kamarudin NA Umar NA Mat NH Khalid BA Diabetes Res Clin Pract 2006 72 48 52 10.1016/j.diabres.2005.09.011 16253380 Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents Dandona P Aljada A J Diabetes Complications 2004 18 91 102 10.1016/S1056-8727(02)00259-3 15120703 Thiazolidinediones in type 2 diabetes – have they lived up to expectations? Bhansali A Modi P J Indian Med Assoc 2005 103 343 346 16225162 Insulin resistance, diabetes and cardiovascular risk: approaches to treatment Rosenberg DE Jabbour SA Goldstein BJ Diabetes Obes Metab 2005 7 642 653 10.1111/j.1463-1326.2004.00446.x 16219008 Iodination by human polymorphonuclear leukocytes Klebanoff SJ Clark RA J Lab Clin Med 1977 89 675 686 839126 Biological defence mechanism. The production by leukocytes of superoxide, a potential bactericidal agent Babior BM Kipnes RS Curnnute JJ J Clin Invest 1973 52 741 744 302313 4346473 10.1172/JCI107236 Neutrophil priming in host defense: role of oxidants as priming agents Swain SD Rohn TT Quinn MT Antioxid Redox Signal 2002 4 69 83 10.1089/152308602753625870 11970845 Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled Annexin V Kuypers FA Lewis RA Hua M Schott MA Discher D Ernst JD Lubin BH Blood 1996 87 1179 1187 8562945 Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus Palumbo PJ J Diabetes Complications 1998 12 110 119 10.1016/S1056-8727(97)00053-6 9559489 Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents Ajjan RA Grant PJ Diab Vasc Dis Res 2006 3 147 158 10.3132/dvdr.2006.023 17160909 Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats Onuta G Rienstra H de Boer JF Boer MW Roks AJ Klatter FA Uges DR Navis G Rozing J Hillebrands JL Transplantation 2007 84 517 526 10.1097/01.tp.0000276983.91892.99 17713437 Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects Pfützner A Weber MM Forst T Expert Opin Pharmacother 2007 8 1985 1998 10.1517/14656566.8.12.1985 17696799 Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention Mazzone T Am J Med 2007 120 9 Suppl 2 S26 32 10.1016/j.amjmed.2007.07.005 17826043 Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction Mittermayer F Schaller G Pleiner J Krzyzanowska K Kapiotis S Roden M Wolzt M J Clin Endocrinol Metab 2007 92 2574 2580 10.1210/jc.2006-2130 17473072 Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study Orio F Manguso F Di Biase S Falbo A Giallauria F Labella D Tolino A Lombardi G Colao A Palomba S Eur J Endocrinol 2007 157 69 73 10.1530/EJE-07-0133 17609404